Eurofins Discovery’s Post

🚀 𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐚 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐢𝐧 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 🚀 Summit Therapeutics, Inc. has recently shared encouraging Phase 3 trial data for their experimental drug, 𝐢𝐯𝐨𝐧𝐞𝐬𝐜𝐢𝐦𝐚𝐛, in the treatment of advanced non-small cell lung cancer (NSCLC). This innovative therapy, a 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 targeting both PD-1 and VEGF pathways, has shown remarkable potential when compared to Merck’s Keytruda. 🎯 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬: • 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧-𝐅𝐫𝐞𝐞 𝐒𝐮𝐫𝐯𝐢𝐯𝐚𝐥: Ivonescimab nearly doubled the time tumors remained stable (11+ months vs. 6 months for Keytruda). 📊 • 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦: By simultaneously targeting PD-1 and VEGF, ivonescimab may offer enhanced efficacy in halting tumor growth. 💡 • 𝐑𝐞𝐝𝐮𝐜𝐞𝐝 𝐑𝐢𝐬𝐤: A 49% reduction in cancer progression or death was observed in the trial. 🔄 However, while these results are highly promising, there are still 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐮𝐧𝐤𝐧𝐨𝐰𝐧𝐬: • ❓The study didn’t include the current standard combination of 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚 + 𝐜𝐡𝐞𝐦𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲, which raises questions about the drug’s comparative performance. • 🌍The trial was conducted in China, so the 𝐠𝐞𝐧𝐞𝐫𝐚𝐥𝐢𝐳𝐚𝐛𝐢𝐥𝐢𝐭𝐲 of the results needs further validation. 🔬 𝐅𝐮𝐫𝐭𝐡𝐞𝐫 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 are underway to answer these questions, and the global medical community eagerly awaits more data, including overall survival rates. If successful, ivonescimab could reshape the treatment landscape for lung cancer patients worldwide. #InnovationInOncology #LungCancer #Ivonescimab #ClinicalTrials #CancerResearch #Pharma

Excellent recent review on ADCs.

Happy Friday all - hope you had a fantastic 4th of July! Check out this open access Trends in Pharmaceutical Sciences review by Jessica M. Konen, Haoyi Wu, and Don L. Gibbons, "Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities." https://lnkd.in/gV3pdRMv Abstract: Immune checkpoint blockade (ICB) therapy works by inhibiting suppressive checkpoints that become upregulated after T cell activation, like PD-1/PD-L1 and CTLA-4. While the initial FDA approvals of ICB have revolutionized cancer therapies and fueled a burgeoning immuno-oncology field, more recent clinical development of new agents has been slow. Here, focusing on lung cancer, we review the latest research uncovering tumor cell intrinsic and extrinsic ICB resistance mechanisms as major hurdles to treatment efficacy and clinical progress. These include genomic and non-genomic tumor cell alterations, along with host and microenvironmental factors like the microbiome, metabolite accumulation, and hypoxia. Together, these factors can cooperate to promote immunosuppression and ICB resistance. Opportunities to prevent resistance are constantly evolving in this rapidly expanding field, with the goal of moving toward personalized immunotherapeutic regimens. #drugdiscovery #cancerresearch #tme #icb #hypoxia #metabolism #microbiome #immunotherapy #immunooncology #scientificresearch

Interested in KRAS? Tempus is presenting Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development at RAS-Targeted Drug Development Summit 2024 KRAS G12C is only the first druggable alteration in RAS genes. Tempus’ multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients including KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence response to RAS neoantigen vaccines, revealing critical insights for targeted therapy development. Gain perspective on the significance of RAS alteration patterns to outcomes to standard of care and their potential to guide precision oncology, enhancing treatment efficacy and patient outcomes. Not attending? Let's connect! #PrecisionOncology #ClinicalDevelopment #BiomarkerStrategy #RAS #KRAS #NRAS #G12C

This new ADC review article entitled "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development" is one of best ADC review papers I have ever read. Thus, highly recommend it!

This brand-new paper regarding database of MHC (Major Histocompatibility Complex) epitopes was published in Antibody Therapeutics. The authors of this paper have developed a comprehensive database of MHC epitopes, experimentally validated for their MHC binding and cell surface presentation. This database catalogs 451,065 MHC peptide epitopes, each with experimental evidence for MHC binding, along with detailed information on human leukocyte antigen allele specificity, source peptides, and references to original studies. They also provide the grand average of hydropathy scores and predicted immunogenicity for the epitopes. The database (MHCepitopes) has been made available on the web and can be accessed at https://lnkd.in/gjVK7N_w. The corresponding author of this paper is Dr. Chongming Jiang at Terasaki Institute for Biomedical Innovation (TIBI). This is an collaborative work from multiple industrial and academic organizations including BioMap (Cheng-chi (CC) Chao), University of Southern California (Siliangyu Cheng), and California State University, Northridge (Bingbing Li). Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics (2023 CiteScore: 8.7), is an international peer-reviewed, open access journal published by Oxford University Press. You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal. https://lnkd.in/gsTu_U2

🎄 Day 6 of the Bispecific Antibody Advent Calendar 🎄 Today, we’re spotlighting Teclistamab (Tecvayli®), a bispecific antibody offering new possibilities for patients with multiple myeloma. 🧪 Key Facts About Teclistamab: Approval year: 2022 Manufacturer: Janssen Biotech Target: BCMA (B-cell maturation antigen) and CD3 Indication: Relapsed or refractory multiple myeloma ✨ How It Works: Teclistamab is designed to redirect T-cells toward cancer cells by binding to BCMA, a protein highly expressed in multiple myeloma cells, and CD3 on T-cells. This initiates T-cell activation and targeted elimination of cancer cells. 📌 Why It Matters: For hard-to-treat cases: Teclistamab provides a new option for patients who have exhausted other therapies. Off-the-shelf therapy: As an antibody treatment, it doesn’t require patient-specific customization like CAR-T therapies. 💡 The Impact: Teclistamab exemplifies the power of bispecific antibodies to deliver effective and accessible solutions for complex cancers. What role do you think bispecifics will play in the future of oncology? Share your thoughts below! #AdventCalendar #BispecificAntibodies #Tecvayli #MultipleMyeloma #Innovation #evitria

📚 Major Histocompatibility complex is a set of genes located on chromosome 6 that play a crucial role in the immune system. While important, it is is difficult to study due to the genetic diversity. 🚀 Good to hear about the MHCepitopes database which contains 451,065 MHC peptide epitopes!

Nature Reviews Cancer article outlining the scientific, clinical and economic rationale for creating a platform to conduct ctDNA-guided clinical trials in the MED (molecular evidence of disease) setting after curative-intent therapy for early-stage cancer Co-authored by Eric Lander, Levi Garraway Nikhil Wagle et al. 1) Standing platform — an infrastructure to support ongoing identification and trial enrolment of patients with cancer with early MED after curative-intent therapy for early-stage cancer, based on the presence of circulating tumour DNA. 2) MED strongly predicts subsequent recurrence, with the vast majority of patients showing radiographic evidence of disease within 18 months. 3) Such a platform would allow efficient testing of many treatments, from small exploratory studies to larger pivotal trials. 4) Trials enrolling patients with MED but without radiographic evidence of disease have the potential to advance drug evaluation because they can be smaller (given high probability of recurrence) and faster (given short time to recurrence) than conventional adjuvant trials. 5) Circulating tumour DNA may also provide a valuable early biomarker of treatment effect, which would allow small signal-finding trials. https://lnkd.in/eYVaE4PU #medicine #research #healthcare #health #drugdevelopment #pharmaceutical #oncology #cancer #cancerresearch #innovation #technology

Great article highlighting the use of ctDNA as an early marker for disease recurrence. Thanks for sharing!